AMGEN Inc
NASDAQ: AMGN
$279.48
-$0.53 (-0.2%)
Real Time Data Delayed 15 Min.
AMGN Articles
DaVita Healthcare Partners has a large amount of cash on its balance sheet and it does not pay a dividend. Should investors should expect a big stock buyback?
Published:
One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases.
Published:
24/7 Wall St. has reviewed the top biotech companies, and the February 27 short interest data have been compared with the mid-February figures. Across the board, all the selected stocks have seen...
Published:
The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Here are the four top biotech stocks to buy now according to Deutsche Bank. These leaders have established drugs, solid pipelines and, most importantly, earnings.
Published:
The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Logically, it seems that as they stock market zooms higher, insiders who want to buy stock would wait until a pullback to add new capital.
Published:
Gilead Sciences has become so large and accumulated enough capital that it has decided to begin paying a dividend, a move follows Amgen.
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. For the majority of the selected stocks, short interest is down.
Published:
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Published:
A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.
Published:
The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published:
ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or...
Published:
Last Updated:
ThinkstockAmgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes phase 3 RILOMET-1 and RILOMET-2 studies....
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
Published: